BRPI0510487A - agentes de contraste para estudo por imagens de perfusão do miocárdio - Google Patents

agentes de contraste para estudo por imagens de perfusão do miocárdio

Info

Publication number
BRPI0510487A
BRPI0510487A BRPI0510487-4A BRPI0510487A BRPI0510487A BR PI0510487 A BRPI0510487 A BR PI0510487A BR PI0510487 A BRPI0510487 A BR PI0510487A BR PI0510487 A BRPI0510487 A BR PI0510487A
Authority
BR
Brazil
Prior art keywords
myocardial perfusion
contrast agents
imaging study
perfusion imaging
patient
Prior art date
Application number
BRPI0510487-4A
Other languages
English (en)
Inventor
Heike S Radeke
David S Casebier
Michael T Azure
Douglas D Dischino
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of BRPI0510487A publication Critical patent/BRPI0510487A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0427—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0419—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

AGENTES DE CONTRASTE PARA ESTUDO POR IMAGENS DE PERFUSãO DO MIOCáRDIO. A presente invenção refere-se, em parte, a compostos e métodos para estudo por imagens de perfusão do miocárdio, compreendendo administrar a um paciente um agente de contraste o qual compreende um composto que liga MC-1, e uma porção para estudo por imagens, e triar o paciente usando diagnóstico por estudo por imagens.
BRPI0510487-4A 2004-04-28 2005-04-27 agentes de contraste para estudo por imagens de perfusão do miocárdio BRPI0510487A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56614604P 2004-04-28 2004-04-28
US11/113,486 US7485283B2 (en) 2004-04-28 2005-04-25 Contrast agents for myocardial perfusion imaging
PCT/US2005/014459 WO2005105159A2 (en) 2004-04-28 2005-04-27 Contrast agents for myocardial perfusion imaging

Publications (1)

Publication Number Publication Date
BRPI0510487A true BRPI0510487A (pt) 2007-11-13

Family

ID=35187299

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510487-4A BRPI0510487A (pt) 2004-04-28 2005-04-27 agentes de contraste para estudo por imagens de perfusão do miocárdio

Country Status (15)

Country Link
US (3) US7485283B2 (pt)
EP (2) EP1740225A4 (pt)
JP (1) JP2007535547A (pt)
KR (1) KR101207216B1 (pt)
CN (1) CN101843908B (pt)
AU (1) AU2005238080B2 (pt)
BR (1) BRPI0510487A (pt)
CA (1) CA2564737C (pt)
ES (1) ES2744544T3 (pt)
IL (1) IL178911A (pt)
MX (1) MXPA06012299A (pt)
NO (1) NO20065048L (pt)
RU (1) RU2006141979A (pt)
SG (1) SG152254A1 (pt)
WO (1) WO2005105159A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
WO2004030659A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
JP2007533634A (ja) * 2003-09-30 2007-11-22 アキュスフィア， インコーポレイテッド 注射、経口、または局所用の徐放性医薬製剤
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
EP1888059B1 (en) 2005-06-01 2014-12-17 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US7824659B2 (en) * 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
PL1933821T3 (pl) 2005-09-15 2021-01-11 Ptc Therapeutics, Inc. Warianty łańcucha końcowego środków terapeutycznych o aktywności redoks do leczenia chorób mitochondrialnych i innych stanów oraz do modulacji biomarkerów energetycznych
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0525949D0 (en) 2005-12-21 2006-02-01 Hammersmith Imanet Ltd Pet radiotracers
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
WO2008133730A2 (en) * 2006-11-15 2008-11-06 The Regents Of The University Of California Labeled rotenone analogs
WO2009110984A2 (en) * 2008-02-29 2009-09-11 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
WO2010004464A1 (en) * 2008-07-09 2010-01-14 Koninklijke Philips Electronics N.V. Physiological pharmacokinetic analysis for combined molecular mri and dynamic pet imaging
LT3827815T (lt) 2008-09-10 2023-10-10 Ptc Therapeutics, Inc. Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais
EP2419096B1 (en) 2009-04-15 2019-11-13 Lantheus Medical Imaging, Inc. Stabilization of radiopharmaceutical compositions using ascorbic acid
CN102858752B (zh) 2010-02-08 2018-10-16 兰休斯医疗成像公司 用于合成显像剂和其中间体的方法和装置
AU2012304359B2 (en) 2011-09-09 2016-11-17 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
CN104771766A (zh) * 2015-05-07 2015-07-15 张国明 心肌灌注成像的造影剂及制备方法
JP6905527B2 (ja) 2015-12-17 2021-07-21 ピーティーシー セラピューティクス， インコーポレイテッド 酸化ストレス障害を処置するためのフルオロアルキル、フルオロアルコキシ、フェノキシ、ヘテロアリールオキシ、アルコキシ、およびアミノ１，４−ベンゾキノン誘導体
EP3203256A1 (en) * 2016-02-02 2017-08-09 B. Braun Melsungen AG Calibration of mri systems using pre-defined concentrations of 19f isotopes as reference
CN106543117B (zh) * 2016-11-10 2019-01-22 南京中医药大学 具有抗肿瘤活性的间双四氢呋喃型番荔枝内酯类化合物及其制备方法与应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1073999A (en) * 1965-01-29 1967-06-28 Ncr Co Process for forming stable images in photochromic material
EP0169375B1 (en) 1984-06-23 1989-12-20 Nissan Chemical Industries Ltd. Process for producing 2-tert.-butyl-4,5-dichloro-3(2h)-pyridazinone
US5393512A (en) 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
JPH07110815B2 (ja) * 1985-11-18 1995-11-29 ボ−ド・オブ・リ−ジェンツ、ザ・ユニバ−シティ−・オブ・テキサス・システム 画像及びスペクトル向上（およびスペクトルシフト）のためのポリキレ−ト剤
JPS6315974A (ja) 1986-07-09 1988-01-23 小泉コンピユ−タ−株式会社 ボ−リングゲ−ム点数表表示装置
US5252317A (en) * 1986-11-10 1993-10-12 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid
US5567411A (en) * 1986-11-10 1996-10-22 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group
IT1229684B (it) 1989-04-05 1991-09-06 Mini Ricerca Scient Tecnolog Piridazinoni ad attivita' insetticida ed acaricida
US5087440A (en) * 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
GB8923843D0 (en) * 1989-10-23 1989-12-13 Salutar Inc Compounds
US5377681A (en) 1989-11-13 1995-01-03 University Of Florida Method of diagnosing impaired blood flow
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5679810A (en) * 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
GB9006977D0 (en) 1990-03-28 1990-05-23 Nycomed As Compositions
WO1992017215A1 (en) 1990-03-28 1992-10-15 Nycomed Salutar, Inc. Contrast media
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5306482A (en) 1991-04-09 1994-04-26 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5093105A (en) 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
WO1993004702A1 (en) 1991-08-29 1993-03-18 Mallinckrodt Medical, Inc. Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
US5169942A (en) 1991-11-21 1992-12-08 General Electric Company Method for making 2-(18F)fluoro-2-deoxy-D-glucose
US5760191A (en) * 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
CA2134549A1 (en) 1993-03-22 1994-09-29 Bruce F. Johnson Method for making 2-fluoro-2 deoxyglucose
CA2158249A1 (en) 1993-03-31 1994-10-13 James W. Brodack Radiopharmaceutical formulations having non-stannous reductants
US5417959A (en) * 1993-10-04 1995-05-23 Mallinckrodt Medical, Inc. Functionalized aza-crytand ligands for diagnostic imaging applications
AU7312694A (en) 1994-06-03 1996-01-04 Mallinckrodt Medical, Inc. Rapidly clearing technetium-99m phosphonate skeletal imaging agents
US5520904A (en) * 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
EP0727225A3 (en) 1995-02-14 1997-01-15 Sonus Pharma Inc Compositions and methods for directed ultrasonic imaging
US5587491A (en) 1995-03-15 1996-12-24 Regents Of The University Of Minnesota Method for the synthesis of bis-tetrahydrofuranyl Annonaceous acetogenins
US5801228A (en) * 1995-06-07 1998-09-01 Nycomed Imaging As Polymeric contrast agents for medical imaging
US6066309A (en) 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5804161A (en) * 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US5677467A (en) 1996-10-03 1997-10-14 Regents Of The University Of Minnesota Synthesis of acetogenins
US6565889B2 (en) * 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US6056939A (en) 1998-08-28 2000-05-02 Desreux; Jean F. Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals
AU1309100A (en) 1998-09-29 2000-04-17 Merck & Co., Inc. Radiolabeled neurokinin-1 receptor antagonists
US6645508B1 (en) 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
WO2002020008A1 (en) 2000-09-06 2002-03-14 The Scripps Research Institute Inhibitors of nadh:ubiquinone oxidoreductase
TWI247609B (en) 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
US20030044354A1 (en) * 2001-08-16 2003-03-06 Carpenter Alan P. Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release
US7344702B2 (en) * 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
CA2463579A1 (en) 2001-10-16 2003-04-24 Hypnion, Inc. Treatment of cns disorders using cns target modulators
CN100577213C (zh) 2002-02-06 2010-01-06 约翰·霍普金斯大学 使用放射性同位素标示亲油性盐的用于线粒体机能障碍的非侵入性诊断显像技术
KR101061561B1 (ko) 2002-03-29 2011-09-02 얀센 파마슈티카 엔.브이. 대사자극성 글루타메이트 수용체 리간드로서 방사능표지된 퀴놀린 및 퀴놀리논 유도체 및 그의 용도
AU2003224747A1 (en) 2002-04-08 2003-10-27 Biostream, Inc. Technetium-labeled rotenone derivatives, and methods of use thereof
GB0229683D0 (en) 2002-12-20 2003-01-29 Imaging Res Solutions Ltd Preparation of radiopharmaceuticals
GB0317920D0 (en) 2003-07-31 2003-09-03 Amersham Plc Solid-phase synthesis
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
US20060083681A1 (en) 2004-10-18 2006-04-20 Ajay Purohit Compounds for myocardial perfusion imaging
KR100789847B1 (ko) 2004-12-15 2007-12-28 (주)퓨쳐켐 알코올 용매하에서 유기플루오로 화합물의 제조방법
WO2007001940A2 (en) 2005-06-23 2007-01-04 Emory University Imaging agents
US7824659B2 (en) 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
WO2007148088A2 (en) 2006-06-21 2007-12-27 Ge Healthcare Limited Radiopharmaceutical products
GB0718386D0 (en) 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
WO2009110984A2 (en) 2008-02-29 2009-09-11 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
CN101555232B (zh) 2009-05-21 2011-01-05 北京师范大学 氟-18标记哒嗪酮类化合物及制备方法和应用
CN102858752B (zh) 2010-02-08 2018-10-16 兰休斯医疗成像公司 用于合成显像剂和其中间体的方法和装置

Also Published As

Publication number Publication date
WO2005105159A3 (en) 2006-04-27
EP1740225A4 (en) 2009-08-19
US20050244332A1 (en) 2005-11-03
MXPA06012299A (es) 2006-12-15
NO20065048L (no) 2006-11-03
IL178911A (en) 2013-10-31
EP1740225A2 (en) 2007-01-10
US20090104118A1 (en) 2009-04-23
ES2744544T3 (es) 2020-02-25
AU2005238080B2 (en) 2011-02-10
US7485283B2 (en) 2009-02-03
EP2253333B1 (en) 2019-06-12
AU2005238080A1 (en) 2005-11-10
US8263042B2 (en) 2012-09-11
RU2006141979A (ru) 2008-06-10
SG152254A1 (en) 2009-05-29
CA2564737A1 (en) 2005-11-10
WO2005105159A2 (en) 2005-11-10
JP2007535547A (ja) 2007-12-06
KR20070007859A (ko) 2007-01-16
CN101843908B (zh) 2014-09-10
US20130028837A1 (en) 2013-01-31
EP2253333A2 (en) 2010-11-24
IL178911A0 (en) 2007-03-08
CN101843908A (zh) 2010-09-29
CA2564737C (en) 2014-03-18
KR101207216B1 (ko) 2012-12-03
EP2253333A3 (en) 2013-05-08

Similar Documents

Publication Publication Date Title
BRPI0510487A (pt) agentes de contraste para estudo por imagens de perfusão do miocárdio
BRPI0507684B8 (pt) agentes de contraste para imagem de perfusão miocárdica
WO2009110984A3 (en) Contrast agents for applications including perfusion imaging
BRPI0513812B8 (pt) método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical
BRPI0515175A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
BRPI0518302A2 (pt) mÉtodo de formaÇço de imagens por rm
WO2007010534A3 (en) Imaging protocols
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
WO2008010227A3 (en) Imaging protocols
CR10091A (es) Compuestos orgánicos
BR112014012822A2 (pt) radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2
NO20082837L (no) Isotopmerkede benzotiazolforbindelser som avbildningsmidler for amyloidogene proteiner
ATE555814T1 (de) Radioaktive mittel für die in vivo pet-bildgebung von ccr5
BRPI0416528A (pt) agente de formação de imagem, composição farmacêutica, composição radiofarmacêutica, conjugado, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
BR0109502A (pt) Molécula de interesse farmacêutico, composição farmacêutica, vacina, método de diagnóstico in vitro de patologias associadas com a presença em um corpo de paciente de ligandos do mhc, pacote ou kit para execução de métodos de diagnóstico in vitro, utilizações de um ligando e de um ácido forte, e, processo de preparação e de estabilização de uma molécula de interesse farmacêutico
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
NO20054615L (no) Mikrobolgemetode
UY30596A1 (es) Marcacion con fluor radioactivo
BRPI0620229A8 (pt) formulação
BRPI0515894A (pt) agente de formação de imagem, composições farmacêutica e radiofarmacêutica, conjugado de um inibidor de metaloproteinase matricial com um ligando, precursor para a preparação da composição radiofarmacêutica, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
MX2008008185A (es) Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer.
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios
WO2008026051A3 (en) 68ga-labelling of a free and macromolecule conjugated macrocyclic chelator at ambient temperature
BRPI0607851A2 (pt) compostos e usos dos mesmos
BR112013006536A2 (pt) agente de formação de imagem, conjugado quelador, métodos de preparação do agente de formação de imagem, de formar imagem do corpo humano ou de animal e de diagnóstico do corpo humano ou animal, composição radiofarmacêutica, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem, da composição ou do kit

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]